GLP-1 heart rate increase and hypersensitivity warning: what the labels say

Short answer: every US label for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity reports a small mean rise in resting heart rate (about 1 to 4 beats per minute vs placebo) and carries a Hypersensitivity Reactions warning for serious allergic reactions such as anaphylaxis and angioedema. Wegovy and Saxenda elevate heart rate to its own section 5 warning and tell clinicians to monitor heart rate at regular intervals. Serious hypersensitivity is also a contraindication on every label. Below are the bpm figures, the section numbers and what the Canadian monographs add.

On this page: US heart rate · US hypersensitivity · Canada · Signs to watch · What to log

Heart rate increase on the US labels

All eight DailyMed labels (checked November 5, 2026) describe a mean increase in heart rate in clinical trials. Only Wegovy (section 5.9) and Saxenda (section 5.5) put Heart Rate Increase under Warnings and Precautions with a monitoring instruction. The other six place the bpm data in Adverse Reactions (section 6.1).

Medication	Where it appears	Monitor?	Trial heart-rate finding (US label)
Ozempic (semaglutide injection)	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +2 to 3 bpm on 0.5 and 1 mg; placebo −0.3 bpm
Wegovy (semaglutide)	5.9 Heart Rate Increase	Monitor heart rate at regular intervals	Mean resting +1 to 4 bpm vs placebo; max change 10–19 bpm in 41% vs 34%; ≥20 bpm in 26% vs 16%; pediatric ≥20 bpm 54% vs 39%
Rybelsus / Ozempic tablets	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +1 to 3 bpm on 7 and 14 mg; placebo no change
Mounjaro (tirzepatide)	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +2 to 4 bpm vs +1 bpm on placebo; sinus tach with ≥15 bpm rise: 4.6% / 5.9% / 10% on 5 / 10 / 15 mg vs 4.3% placebo
Zepbound (tirzepatide)	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +1 to 3 bpm (Studies 1 and 2 pool); no increase on placebo
Saxenda (liraglutide 3 mg)	5.5 Heart Rate Increase	Monitor heart rate at regular intervals	Mean resting +2 to 3 bpm; >10 bpm at two visits 34% vs 19%; >20 bpm 5% vs 2%; resting >100 bpm once 6% vs 4%; tachycardia AE 0.6% vs 0.1%
Victoza (liraglutide)	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +2 to 3 bpm from baseline vs placebo in adults
Trulicity (dulaglutide)	6.1 (Adverse Reactions)	No separate §5 HR warning	Mean +2 to 4 bpm on 0.75 and 1.5 mg; sinus tach AE 2.8% / 5.6% vs 3.0% placebo; ≥15 bpm rise 1.3% / 2.2% vs 0.7%

These are mean changes across trial populations, not a target pulse and not a dosing rule. Larger single-visit jumps (10–20+ bpm) appear more often than the mean suggests on Wegovy and Saxenda. Mounjaro and Trulicity also report sinus-tachycardia-type adverse reactions with a ≥15 bpm rise from baseline.

Hypersensitivity (allergic) reactions on the US labels

Every product warns that serious hypersensitivity reactions have been reported. The shared actions are: discontinue the drug if a reaction is suspected, treat promptly, seek medical advice, and do not restart in someone with a prior serious reaction to that drug or its ingredients. Most labels also say to use caution if the person had anaphylaxis or angioedema with another GLP-1 receptor agonist, because cross-reactivity is unknown.

Medication	Section	Warning summary	Also a contraindication?
Ozempic	5.8	Serious hypersensitivity (e.g., anaphylaxis, angioedema) reported; discontinue if suspected; seek medical advice; caution after anaphylaxis/angioedema with another GLP-1 RA	Also a contraindication (4)
Wegovy	5.7	Anaphylactic reactions and angioedema reported postmarketing; discontinue if suspected; seek medical advice promptly	Also a contraindication (prior serious hypersensitivity)
Rybelsus / Ozempic tablets	5.7	Serious hypersensitivity (e.g., anaphylaxis, angioedema) reported; discontinue if reactions occur; monitor until signs resolve	Also a contraindication
Mounjaro	5.4	Serious hypersensitivity (e.g., anaphylaxis, angioedema) reported; discontinue if suspected; seek medical advice promptly	Also a contraindication (known serious hypersensitivity)
Zepbound	5.6	Serious hypersensitivity (e.g., anaphylaxis, angioedema) reported postmarketing with tirzepatide; seek medical attention promptly and discontinue	Also a contraindication
Saxenda	5.8	Postmarketing serious hypersensitivity (e.g., anaphylactic reactions, angioedema); discontinue Saxenda and other suspect medicines; seek medical advice; caution after anaphylaxis/angioedema with another GLP-1 RA	Also a contraindication
Victoza	5.7	Postmarketing serious hypersensitivity (e.g., anaphylactic reactions, angioedema); discontinue; seek medical advice; caution after anaphylaxis/angioedema with another GLP-1 RA	Also a contraindication
Trulicity	5.4	Serious hypersensitivity (e.g., anaphylactic reactions, angioedema) have occurred; discontinue; seek medical advice; caution after angioedema/anaphylaxis with another GLP-1 RA	Also a contraindication; systemic HS in trials 0.5%

Trulicity is the clearest on trial incidence: systemic hypersensitivity adverse reactions, sometimes severe (severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adults on Trulicity in clinical studies. Injection-site reactions were reported separately (0.5% on Trulicity vs 0.0% on placebo in placebo-controlled adult studies). Other products mainly describe serious reactions in postmarketing experience, so a precise rate is not given.

Canada: cardiovascular and immune monograph wording

Canadian product monographs place Heart Rate Increase under Cardiovascular warnings for all eight products, and hypersensitivity under Immune. They often add clinical caution for people with tachyarrhythmias or ischemic heart disease, which the US Adverse Reactions sections usually omit.

Monograph	Heart rate and hypersensitivity (summary)
Ozempic	Cardiovascular: Heart Rate Increase — causes an increase in heart rate; caution in cardiac conditions that might be worsened (e.g., tachyarrhythmias). Mean +1–6 bpm in placebo- and active-controlled trials; placebo −0.3 bpm. Immune: serious HS including anaphylaxis may occur; discontinue and seek medical advice; caution after angioedema/anaphylaxis with another GLP-1 RA.
Wegovy	Cardiovascular: Heart Rate Increase — monitor heart rate at regular intervals; tell HCP about palpitations or racing heartbeat at rest; discontinue if sustained increase in resting heart rate. Phase 3a mean +3 bpm from baseline ~72 bpm. Immune: severe life-threatening generalized allergic reactions including anaphylaxis have occurred; discontinue and seek medical advice.
Rybelsus	Cardiovascular: Heart Rate Increase — causes an increase in heart rate; caution in tachyarrhythmias. Mean +1 to 3 bpm on 7 and 14 mg; placebo no change. Immune: serious HS including anaphylaxis may occur; discontinue and seek medical advice; caution after angioedema/anaphylaxis with another GLP-1 RA.
Mounjaro	Cardiovascular: Heart Rate Increase — causes an increase in heart rate; caution if cardiac conditions might be worsened. Mean +2 to 4 bpm vs +0.7 bpm on placebo; caution with other drugs that also raise heart rate. Immune: HS reported in trials; postmarketing serious HS (anaphylactic reactions, angioedema); discontinue; caution after angioedema/anaphylaxis with a GLP-1 RA.
Zepbound	Cardiovascular: Heart Rate Increase — mean +3 bpm vs no increase on placebo in the cited pool; caution with other drugs that raise heart rate. Immune: HS reported in trials; postmarketing serious HS (anaphylactic reactions, angioedema) with tirzepatide; discontinue; caution after angioedema/anaphylaxis with a GLP-1 RA or related products.
Saxenda	Cardiovascular: mean resting +2 to 3 bpm vs placebo; >10 bpm at two visits and >20 bpm more common than placebo; resting >100 bpm once in 6% vs 4%; tachycardia AE 0.6% vs 0.1%. Immune: reports of serious HS (anaphylactic reactions, angioedema); discontinue Saxenda and other suspect medicines; seek medical advice.
Victoza	Cardiovascular: 24 h time-averaged mean heart rate +7 to 8 bpm in healthy volunteers on serial ECG; long-term diabetes trials including LEADER mean +2 to 4 bpm; LEADER noted no long-term adverse clinical impact of increased heart rate on CV event risk. Immune: postmarketing serious HS (anaphylactic reactions, angioedema); discontinue and treat promptly.
Trulicity	Cardiovascular: Heart Rate Increase — may worsen cardiac conditions in people with ischemic heart disease or tachyarrhythmias; mean +2 to 4 bpm; sinus tach AE 3.0% / 2.8% / 5.6% (placebo / 0.75 / 1.5 mg). Immune: systemic HS sometimes severe in 0.5% in Phase 2/3 (0.75 and 1.5 mg); postmarketing serious HS (anaphylactic reactions, angioedema); discontinue.

Notable Canada extras: Wegovy tells patients to report palpitations or a racing heartbeat at rest and to discontinue if resting heart rate rises and stays up; Victoza reports a larger 7–8 bpm 24-hour average rise in a healthy-volunteer ECG study alongside the 2–4 bpm long-term diabetes-trial figure; Ozempic's Canadian mean range is written as 1–6 bpm (broader than the US placebo-controlled 2–3 bpm line).

Signs the labels tell patients to take seriously

Heart rate / palpitations: a racing heartbeat while at rest, sustained higher resting pulse, or palpitations — especially called out on the Canadian Wegovy monograph and the US Wegovy/Saxenda monitoring instructions.
Serious allergic reaction: swelling of the face, lips, tongue or throat; trouble breathing or swallowing; severe rash or itching; fainting or feeling dizzy; very rapid heartbeat. Stop the medicine and get medical help right away. In an emergency call 911.
Prior reaction to another GLP-1: tell your prescriber before starting; labels say cross-reactivity is unknown.

What to log and tell your prescriber

Resting pulse (beats per minute), date and time, and whether you were at rest.
Palpitations or a racing heartbeat, and how long they lasted.
Any rash, swelling, breathing trouble or other suspected allergic symptoms, with the date and what happened next.
Any past serious reaction to a GLP-1 or its ingredients (a contraindication on every label here).
Other medicines that also raise heart rate, which several Canadian monographs flag as a caution.

For the other class warnings, see GLP-1 hypoglycemia warning, thyroid warning and contraindications, kidney and dehydration, pancreatitis and gallbladder, aspiration under anesthesia and tracking side effects.

Sources

This page summarizes official product labels as general information. It is not medical advice. Do not start, stop or change any medication based on this page. Labels are updated; check the current version for your product. In an emergency call 911.

Frequently asked questions

Do Ozempic, Wegovy, Mounjaro and Zepbound raise heart rate?

Yes, according to every US label covered here. Mean resting heart rate rose about 1 to 4 beats per minute vs placebo across Ozempic (2–3 bpm), Wegovy (1–4 bpm), Rybelsus (1–3 bpm), Mounjaro (2–4 bpm vs +1 on placebo), Zepbound (1–3 bpm), Saxenda (2–3 bpm), Victoza (2–3 bpm) and Trulicity (2–4 bpm). Wegovy and Saxenda also have a section 5 "Heart Rate Increase" warning that tells clinicians to monitor heart rate at regular intervals.

How often do bigger jumps in heart rate show up in the trials?

The labels that break out larger changes are Wegovy, Saxenda, Mounjaro and Trulicity. On Wegovy, a maximum change of 10–19 bpm occurred in 41% vs 34% on placebo, and 20 bpm or more in 26% vs 16%. On Saxenda, changes of more than 10 bpm at two consecutive visits were 34% vs 19%, and more than 20 bpm 5% vs 2%; at least one resting rate over 100 bpm was recorded in 6% vs 4%. Mounjaro reported sinus tachycardia with a ≥15 bpm rise in 4.6%, 5.9% and 10% on 5, 10 and 15 mg vs 4.3% on placebo. Trulicity reported sinus tachycardia in 2.8% and 5.6% on 0.75 and 1.5 mg vs 3.0% on placebo, and a ≥15 bpm rise in 1.3% and 2.2% vs 0.7%.

Should I stop my GLP-1 if my pulse is higher?

That is your prescriber's decision. The US Wegovy and Saxenda labels say to monitor heart rate at regular intervals. The Canadian Wegovy monograph tells patients to report palpitations or a racing heartbeat at rest, and says to discontinue if there is a sustained increase in resting heart rate. Glidedose does not suggest doses or when to stop.

Can GLP-1s cause serious allergic reactions?

Yes. All eight US labels carry a Hypersensitivity Reactions warning (section numbers differ by product). They say serious reactions such as anaphylaxis and angioedema have been reported, tell clinicians to discontinue the drug if suspected and seek medical advice promptly, and most add caution if the person had anaphylaxis or angioedema with another GLP-1 receptor agonist. Serious hypersensitivity is also a contraindication on every US label and every Canadian monograph covered here.

What are the signs of a serious allergic reaction on these labels?

Patient labeling commonly lists swelling of the face, lips, tongue or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; and a very rapid heartbeat. Stop the medicine and get medical help right away if those occur. In an emergency call 911.

How common were hypersensitivity reactions in the trials?

Most products report serious reactions mainly as postmarketing experience, so a trial rate is not always given. Trulicity's US label says systemic hypersensitivity reactions (sometimes severe: severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of adults on Trulicity in clinical studies. The Canadian Trulicity monograph repeats that 0.5% figure from the Phase 2 and 3 studies of the 0.75 and 1.5 mg doses.

Is there a Canada vs US difference on heart rate?

The Canadian monographs put Heart Rate Increase under Cardiovascular warnings for all eight products we checked, and they often add clinical caution for people with tachyarrhythmias or ischemic heart disease. Mean bpm figures are similar to the US labels (Ozempic CA reports 1–6 bpm in placebo- and active-controlled trials; Wegovy CA mean +3 bpm; Victoza CA notes a 7–8 bpm 24-hour average rise in healthy volunteers on serial ECG, and 2–4 bpm in long-term diabetes trials including LEADER). Only Wegovy and Saxenda among the US labels elevate heart rate to its own section 5 warning with a "monitor at regular intervals" instruction.

Does a higher heart rate mean more heart attacks on these drugs?

The labels that discuss cardiovascular outcomes separately (for example Victoza LEADER and Ozempic SUSTAIN 6 / FLOW) report cardiovascular benefit or risk-reduction indications. The Victoza Canadian monograph says that in LEADER, no long-term adverse clinical impact of increased heart rate on the risk of cardiovascular events was observed. This page only summarizes the heart-rate and hypersensitivity label text; it is not a cardiovascular-outcomes review.

What should I log in a GLP-1 tracker?

Resting pulse (beats per minute), the date and time, whether you were at rest or after activity, and any palpitations. For allergy concerns, log the date, the symptoms (rash, swelling, breathing trouble), and what you did next. Never log a dose change suggested by an app — Glidedose is a GLP-1 tracker for dates and symptoms so you can show your prescriber.

Which section numbers cover these warnings on the US labels?

Heart rate as its own Warnings and Precautions section: Wegovy 5.9, Saxenda 5.5. The other six list mean heart-rate changes under Adverse Reactions (section 6.1). Hypersensitivity: Ozempic 5.8; Wegovy 5.7; Rybelsus 5.7; Mounjaro 5.4; Zepbound 5.6; Saxenda 5.8; Victoza 5.7; Trulicity 5.4. Section numbers can change when labels are revised.

GLP-1 thyroid warning and contraindications
The thyroid C-cell tumor warning, MTC and MEN 2, and each label's warnings, US vs Canada.GLP-1 low blood sugar warning
Hypoglycemia rates from each label alone, with insulin and with sulfonylureas, plus Canada's driving advice.GLP-1 kidney and dehydration warning
Acute kidney injury wording and trial rates from each label, severe GI rates, and Canada's ESRD rules.Tracking GLP-1 side effects
A practical way to log symptoms so your appointments are more useful.GLP-1 aspiration risk under anesthesia
Delayed gastric emptying and pulmonary aspiration warnings from US labels and Canadian monographs for all 8 GLP-1s.